Skip to main content
SpringerLink
Log in

The Role of Beta-Blockers in the Treatment of Hypertension

  • Chapter
Hypertension: from basic research to clinical practice

Part of the book series: Advances in Experimental Medicine and Biology ((AIM,volume 956))

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

BP:

blood pressure

BB:

beta-blocker

References

  • Al-Wadei HA, Al-wadei MH, Schuller HM (2012) Cooperative regulation of non-small cell lung carcinoma by nicotinic and beta-adrenergic receptors: a novel target for intervention. PLoS One 7:e29915. Epub 2012

    Google Scholar 

  • Barnes MJ, McDougal DH (2014) Leptin into the rostral ventral lateral medulla (RVLM) augments renal sympathetic nerve activity and blood pressure. Front Neurosci 8:232

    PubMed  PubMed Central  Google Scholar 

  • Barron TL, Conolly RM, Sharp L, Bennett K, Visvanathan K (2011) Beta-blockers and breast cancer mortality: a population-based study. J Clin Oncol 29:2635–2644

    Article  CAS  PubMed  Google Scholar 

  • Berglund G, Andersin O, Widgren B (1986) Low-dose antihypertensive treatment with a thiazide diuretic is not diabetogenic. Acta Med Scand 220:419–424

    Article  CAS  PubMed  Google Scholar 

  • Black HR, Elliot WJ, Grandits G, Grambcsh P, Lucente T, White WB et al (2003) Principal results of the Controlled Onset Verapamil Investigation Of Cardiovascular End Points (CONVINCE) Trial. JAMA 289:2073–2082

    Article  CAS  PubMed  Google Scholar 

  • Brooks VL, Shi Z, Holwerda SW, Fadel PJ (2015) Obesity-induced increases in sympathetic nerve activity: sex matters. Auton Neurosci 187:18–26. doi:10.1016/j.Autoneu.2014.11.006, Epub 2014 Nov 20

    Article  PubMed  Google Scholar 

  • Cakir Y, Plummer HK, Tithof PK, Schuller HM (2002) Beta-adrenergic and arachidonic acid-mediated growth regulation of human breast cancer cell lines. Int J Oncol 21:153–157

    CAS  PubMed  Google Scholar 

  • Coats AJS, Cruickshank JM (2014) Hypertensive subjects with type-2 diabetes, the sympathetic nervous system, and treatment implications. Int J Cardiol 174:702–709

    Article  PubMed  Google Scholar 

  • Cole SW, Sood AK (2012) Molecular pathways: beta-adrenergic signaling in cancer. Clin Cancer Res 18:1201–1206

    Article  CAS  PubMed  Google Scholar 

  • Coope J, Warrender TS (1986) Randomised trial of treatment of hypertension in elderly patients in primary care. BMJ 293:1145–1151

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Cruickshank JM (2013) Essential hypertension. People’s Publishing House, Shelton

    Google Scholar 

  • Cruickshank JM (2014) The unholy alliance between obesity, type-2 diabetes, the sympathetic nervous system, and hypertension in young/middle-aged subjects. J Mol Genet Med S1. http://dd.org/10.4172/1747-0862.S1-016

  • Cruickshank JM, Prichard BNC (1994) Beta-blockers in clinical practice (2nd edn). Churchill Livingstone, Edinburgh, pp 1–351

    Google Scholar 

  • Cryer PE, Haymond MW, Satiago JV, Shar SP (1976) Norepinephrine and epinephrine release and adrenergic mediation of smoking-associated hemodynamic and metabolic events. N Engl J Med 295:573–577

    Article  CAS  PubMed  Google Scholar 

  • Dahlof B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO (1991) Morbidity and mortality in the Swedish Trial in Old Patients with hypertension (STOP-Hypertension). Lancet 338:1281–1285

    Article  CAS  PubMed  Google Scholar 

  • Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U et al (2002) LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359:995–1003

    Article  CAS  PubMed  Google Scholar 

  • Dahlof B, Sever PS, Poulter NR et al (2005) Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandanavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366:895–906

    Article  PubMed  Google Scholar 

  • De Giorgi V, Gandini S, Grazzini M, Benemai S, Marchionni N, Geppetti P (2012) Beta-blockers: a new and emerging treatment for melanoma. Recenti Prog Med 103:11–16

    PubMed  Google Scholar 

  • Deary AJ, Schumann AL, Murfeet H, Haydock SF, Foo RS, Brown MJ (2002) Double-blind, placebo controlled crossover comparison of 5 classes of drugs. J Hypertens 20:771–777

    Article  PubMed  Google Scholar 

  • Druktenis JS, Roman MJ, Fabsitz RR, Lee ET, Best LG, Russel M et al (2007) Cardiac and systemic hemodynamic characteristics of hypertension and prehypertension in adolescents and young adults. The Strong Heart Study. Circulation 115:221–227

    Article  Google Scholar 

  • Eriksson S, Olofsson B-O, Wester P-O, for the TEST Study Group (1995) Atenolol in secondary prevention after stroke. Cerebrovasc Dis 5:21–25

    Article  Google Scholar 

  • Esler MO, Jennings GL, Johns J, Burke F, Little PJ, Leonard P (1984) Estimation of “total” renal, cardiac and splanchnic sympathetic nervous tone in essential hypertension from measurements of noradrenaline release. J Hypertens Suppl 2(3):S123–S125

    CAS  PubMed  Google Scholar 

  • Estacio RO, Jeffers BW, Hiatt W, Biggerstaff SL, Gifford N, Schrier RW (1998) The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 338:645–652

    Article  CAS  PubMed  Google Scholar 

  • Feldman RD, Limbird LE, Nadeau J, Robertson D, Wood AJ (1984) Alteration in leukocyte beta-receptor affinity with aging. A potential explanation for altered beta-adrenergic sensitivity in the elderly. N Engl J Med 310:815–819

    Article  CAS  PubMed  Google Scholar 

  • Fitzgerald PJ (2012) Beta-blockers, norepinephrine, and cancer: an epidemiological viewpoint. Clin Epidemiol 4:151–156

    Article  PubMed  PubMed Central  Google Scholar 

  • Fogari R, Zoppi A, Coradi L, Preti P, Malalamani GD, Muellini A (2000) Effects of different dihydropyridine calcium antagonists on plasma norepinephrine in essential hypertension. J Hypertens 18:1871–1875

    Article  CAS  PubMed  Google Scholar 

  • Franklin SS, Pio JR, Wong ND, Larson MG, Leip EP, Vasan RS et al (2005) Predictors of new-onset diastolic and systolic hypertension. The Framingham Heart Study. Circulation 111:1121–1127

    Article  PubMed  Google Scholar 

  • Frishman WH, Burris JF, Mroczek WJ, Weir MR, Alemayehu D, Simon JS et al (1995) First-line therapy option with low-dose bisoprolol fumarate and low-dose hydrochlorthiazide in patients with stage 1 and stage 11 systemic hypertension. J Clin Pharmacol 35:182–188

    Article  CAS  PubMed  Google Scholar 

  • Gillman MW, Kannel WB, Belanger A (1993) Influence of heart rate on mortality among persons with hypertension: the Framingham Study. Am Heart J 125:1148–1154

    Article  CAS  PubMed  Google Scholar 

  • Grassi G, Dell Oro R, Facchini A, Quarti Trevano F, Bolla GB, Mancia G (2004) Effect of central and peripheral body fat distribution on sympathetic and baroreflex functionin obese normotensives. J Hypertens 22:236–239

    Google Scholar 

  • Grytli HH, Fagerland MW, Fossa SD, Tasken KA, Hanheim LL (2013) Use of beta-blockers is associated with prostate cancer-specific survival in prostate cancer patients on androgen deprivation therapy. Prostate 73:250–260

    Article  CAS  PubMed  Google Scholar 

  • Haller H, Ito S, Izzo JL, Januszewicz A, Katayama S, Menne J et al (2011) Olmesartan for the delay or prevention of microalbuminuria in type-2 diabetes. N Engl J Med 364:907–917

    Article  CAS  PubMed  Google Scholar 

  • Hammond JJ, Kirkendall WM, Zama A, Thomas JC, Overturf ML (1978) Pindolol, propranolol and chlorthalidone in moderate hypertension. Pharmacologist 20:189

    Google Scholar 

  • Hansson L, Linholm LH, Niskanen L, Lanke J, Hedner T, Niklason A et al (1999a) Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project(CAPP)randomised trial. Lancet 353:611–616

    Article  CAS  PubMed  Google Scholar 

  • Hansson L, Lindholm LH, Ekbom T, Dahlof B, Lanke J, Schersten B et al (1999b) Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 354:1751–1756

    Article  CAS  PubMed  Google Scholar 

  • Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen JO et al (2000) Randomised of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality: the Nordic Diltiazem (NORDIL) study. Lancet 356:359–365

    Article  CAS  PubMed  Google Scholar 

  • Harding JL, Sooriyakumaran M, Anstey KJ, Adam R, Balkau B, Brennan-Olsen S et al (2016) Hypertension, antihypertensive treatment and cancer incidence and mortality: a pooled collaborative analysis of 12 Australian and New Zealand cohorts. J Hypertens 34:149–155

    Article  CAS  PubMed  Google Scholar 

  • Hart EC, Charkoudian N (2014) Sympathetic neural regulation of blood pressure: influence of sex and age. Physiology (Bethesda) 29:8–15

    CAS  Google Scholar 

  • Heidland UE, Strauer BE (2001) Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation 104:1477–1482

    Article  CAS  PubMed  Google Scholar 

  • Helin P, Lorenzen I, Garbash C, Matthiessen ME (1970) Atheroscerosis in rabbit aorta induced by noradrenaline. The importance of the duration of noradrenaline action. Atherosclerosis 12:125–132

    Article  CAS  PubMed  Google Scholar 

  • Heuser K, Vitkovsky J, Raasch W, Schmieder R, Schobel HP (2003) Elevation of sympathetic activity by eprosartan in young male subjects. Am J Hypertens 16:658–664

    Article  Google Scholar 

  • Hiltunen TP, Suonsyrja T, Hanilla-Handelberg T, Paarvonen KJ, Miettinen HE, Strandberg T et al (2007) Predictors of antihypertensive drug responses: initial data from a placebo-controlled, randomesed, cross-over study with foue antihypertensive drugs (The GENRES Study). Am J Hypertens 20(3):311–318

    Article  CAS  PubMed  Google Scholar 

  • Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR (2008) Long-term follow-up after tight control of blood pressure in type-2 diabetes. N Engl J Med 359:1565–1576

    Article  CAS  PubMed  Google Scholar 

  • Huggett RJ, Scott EM, Gilbey SG, Stoker JB, Macintosh AF, Mary DA (2003) Impact of type-2 diabetes on sympathetic neural mechanisms in hypertension. Circulation 108:3097–4101

    Article  CAS  PubMed  Google Scholar 

  • Imai E, Chan JC, Ito S, Yamasaki T, Kobayashi F, Hanada M et al (2011) Effects of olmesartan on renal and cardiovascular outcomes in type-2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study. Diabetologia 54:2978–2986

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Inge TH, Courcoulas AP, Jenkins TM, Michalski MP, Helmrath MA, Brandt MD et al (2016) Weight loss and health status 3 years after bariatric surgery in adolescents. N Engl J Med 374:113–123

    Article  CAS  PubMed  Google Scholar 

  • James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J et al (2014) 2014 evidence-based guideline for the management of high blood pressure in adults. Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 311:507–520

    Article  CAS  PubMed  Google Scholar 

  • Khan N, McAlister FA (2006) Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis. CMAJ 174:1737–1742

    Article  PubMed  PubMed Central  Google Scholar 

  • Khan NA, Hemmelgarn B, Herman RJ, Bell CM, Mahon JL, Leiter LA et al (2009) The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 – therapy. Can J Cardiol 25(5):287–298

    Article  PubMed  PubMed Central  Google Scholar 

  • Kostis V, Nilsson P, Grassi G, Mancia G, Redon J, Luft F et al (2015) New developments in the pathogenesis of obesity-induced hypertension. J Hypertens 33:1499–1508

    Article  Google Scholar 

  • Krause T, Lovibond K, Caufield M, McCormak T, Williams B (2011) Management of hypertension: summary of NICE guidelines. BMJ 343:d4891.doi:10.1136/bmj:d4891

  • Kuyper LM, Kahn NA (2014) Atenolol vs non-atenolol beta-blockers for the treatment of hypertension: a meta-analysis. Can J Cardiol 30(suppl 5):S47–S53

    Article  PubMed  Google Scholar 

  • Lambert E, Straznicky N, Schlaich M, Esler MP, Haikerwal D, Brencley D et al (2007) Differing pattern of sympathoexcitation in normal- weight and obesity-related hypertension. Hypertension 50:862–868

    Article  CAS  PubMed  Google Scholar 

  • Leren P, Heigeland A (1986) Coronary heart disease and treatment of hypertension. The Oslo Study. Am J Med 80:3–6

    Article  CAS  PubMed  Google Scholar 

  • Lindholm LH, Carlberg B, Samuelsson O (2005) Should beta-blockers remain the first choice in the treatment of primary hypertension? A meta-analysis. Lancet 366:1545–1553

    Article  CAS  PubMed  Google Scholar 

  • Mancia G, De Backer G, Dominiczak A, Cifcova R, Fagard R, Gernano G et al (2007) 2007 Guidelines forthe management of arterial hypertension. The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 28:1462–1536

    PubMed  Google Scholar 

  • Medical Research Working Party (1985) MRC trial of treatment of mild hypertension: principle results. BMJ 291:97–104

    Article  Google Scholar 

  • Melhem-Bertrandt A, Chavez-Macgreggor LX, Brown EN, Lee RT, Meric-Bernstam F et al (2011) Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol 29:2645–2652

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Menon DV, Arbique D, Wang Z, Adam-Huet B, Auchus RJ, Vongpatanasin W (2009) Differential effects of chlorthalidone versus spironolactone on muscle sympathetic nerve activity in hypertensive patients. J Clin Endocrinol Metab 94:1361–1366

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Moltzer E, Mattace Raso FU, Karamermer Y, Boersma E, Webb GD, Simoons ML et al (2010) Comparison of candesartan versus metoprolol for treatment of systemic hypertension after repaired aortic coarctation. Am J Cardiol 105:217–222

    Article  CAS  PubMed  Google Scholar 

  • MRC Working Party (1992) Medical Research Council trial of treatment of hypertension in older adults.: principal results. BMJ 304:405–412

    Article  Google Scholar 

  • Neutel JM, Smith DH, Ram CV, Kaplan NM, Papademetriou V, Fagan TC et al (1993) Application of ambulatory blood pressure monitoring in differentiating between antihypertensive agents. Am J Med 94:181–187

    Article  CAS  PubMed  Google Scholar 

  • No author listed (1980) The Australian therapeutic trial in hypertension. Report by the Management Committee. Lancet 1:1261–1267

    Google Scholar 

  • Noll G, Wenzel RR, de Marchi S, Shaw S, Luscher TF (1997) Differential effects of captopril and nitrates on muscle sympathetic nerve activity in volunteers. Circulation 95:2286–2292

    Article  CAS  PubMed  Google Scholar 

  • Norris K, Bourgoigne J, Gassman J, Hibert L, Middleton J, Phillips RA et al (2006) Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial. Am J Kidney Dis 48:739–751

    Article  CAS  PubMed  Google Scholar 

  • Palatini P, Julius S (2009) The role of cardiac autonomic function in hypertension and cardiovascular disease. Curr Hypertens Rep 11:199–205

    Article  PubMed  Google Scholar 

  • Parrinello G, Paterna S, Torres D, Di Pasquale P, Mezzero M, La Rocca G et al (2009) One year renal and cardiac effect of bisoprolol versus losartan in recently diagnosed hypertensive patients. Clin Drug Investig 29:591–600

    Article  CAS  PubMed  Google Scholar 

  • Pasquier E, Street J, Pouchy C, Carre M, Gifford AJ, Murray J et al (2013) Beta-blockers increase response to chemotherapy via direct anti-tumor and anti-angiogenic mechanisms in neuroblastoma. Br J Cancer 108:2485–2494

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Peng Y-X, Shan J, Qi XY, Qi XY, Zhang SJ, Ma SP, Wang N et al (2006) The catecholamine-beta-adrenoceptor-cAMP system and prediction of cardiovascular events in hypertension. Clin Exp Pharmacol Physiol 33:27–231

    Article  Google Scholar 

  • Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH et al (2003) A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomised controlled trial. JAMA 290:2805–2816

    Article  CAS  PubMed  Google Scholar 

  • Perron L, Bairati L, Harel F, Meyer F (2004) Antihypertensive drug use and the risk of prostate cancer (Canada). Cancer Causes Control 15:535–541

    Article  PubMed  Google Scholar 

  • Perrone MG, Notanicola M, Caruso MG, Tutino V, Scilimati A (2008) Upregulation of beta-3adrenergic receptor mRNA in human colon cancer: a preliminary study. Oncology 75:224–229

    Article  CAS  PubMed  Google Scholar 

  • Prisant LM, Mensah GA (1996) Use of beta-adrenergic receptor blockers in blacks. J Clin Pharmacol 36:867–873

    Article  CAS  PubMed  Google Scholar 

  • Prospective Studies Collaboration (2002) Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360:1903–1913

    Article  Google Scholar 

  • Robb OJ, Petrie JC, Webster J, Harry J (1985) ICI 118,551 does not reduce blood pressure in hypertensive patients responsive to atenolol and propranolol. Br J Clin Pharmacol 19:541–542

    Google Scholar 

  • Seravalle G, Lonati L, Buzzi S, Cairo M, Quarti Trevano F, Dell’Oro R et al (2015) Sympathetic nerve traffic and baroreflex function in optimal, normal, and high-normal blood pressure states. J Hypertens 33(7):1411–1417. doi:10.1097/HJH.000000000000567

    Article  CAS  PubMed  Google Scholar 

  • SHEP Cooperative Research Group (1991) Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA 265:3255–3264

    Article  Google Scholar 

  • Sipahi I, Tuzcu M, Wolski KE, Nicholls SJ, Schoenhagen P, Hu B et al (2007) Beta-blockers and progression of coronary atherosclerosis: pooled analysis of 4 intravascular ultrasonography trials. Am Int Med 147:10–18

    Article  Google Scholar 

  • Smith C, Teitler M (1999) Beta-blocker selectivity at cloned human beta-1 and beta-2 adrenergic receptors. Carsiovasc Drugs Ther 13:126–127

    Google Scholar 

  • Sowers JR, Lester M (2000) Hypertension, hormones and aging. J Lab Clin Med 135:379–386

    Article  CAS  PubMed  Google Scholar 

  • Straus MH, Hall AS (2007) Renin-angiotensin system and cardiovascular talk. Lancet 370:23–24

    Article  Google Scholar 

  • Strauss MH, Hall AS (2006) Angiotensin receptor blockers may increase the risk of myocardial infarction. Circulation 114:838–854

    Article  PubMed  Google Scholar 

  • Takezaki T, Hamajima N, Maisuo K, Tanaka R, Hirai T, Kato T et al (2001) Association of polymorphisms in the beta-2 and beta-3 adrenoceptor genes with risk of colorectal cancer in Japanese. Int J Clin Oncol 6:117–122

    Article  CAS  PubMed  Google Scholar 

  • Tarnow J, Muller RK (1991) Cardiovascular effects of low-dose epinephrine infusions in relation to the extent of pre-operative beta-blockade. Anaesthesiology 74:1035–1043

    Article  CAS  Google Scholar 

  • Tenero DM, Bottorf MB, Burlew BS, Williams JB, Lalande RL (1990) Altered beta-adrenergic sensitivity and protein binding to I-propranolol in the elderly. Cardiovasc Pharmacol 16:702–707

    Article  CAS  Google Scholar 

  • The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) Major outcomes in high-risk hypertensive patients randomised to ACE-inhibitor or calcium channel blocker vs diuretic. JAMA 288:2981–2997

    Article  Google Scholar 

  • The IPPPSH Collaborative Group (1985) Cardiovascular risk and risk factors in a randomised trial of treatment based on the beta-blocker oxprenolol: the International prospective primary prevention study in hypertension (IPPPSH). J Hypertens 3:379–392

    Article  Google Scholar 

  • Thomopoulos C, Parati G, Zanchetti A (2015a) Effects of blood pressure-lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs –Overview and meta-analysis. J Hypertens 33:195–211

    Article  CAS  PubMed  Google Scholar 

  • Thomopoulos C, Parati G, Zanchetti A (2015b) Effects of blood pressure-lowering on outcome incidence in hypertension: head-to-head comparisons of various classes of antihypertensive drugs – overview and meta-analyses. J Hypertens 33:1321–1341

    Article  CAS  PubMed  Google Scholar 

  • Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling stroke. The Dutch TIA Trial Study Group. Stroke 24:543–548 (1993)

    Google Scholar 

  • U.K. Prospective Diabetes Study Group (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type-2 diabetes. UKPDS 38. BMJ 317:703–713

    Google Scholar 

  • UK Prospective Diabetes Study Group (1998) Efficacy of atenolol and captopril reducing risk of macrovascular and microvascular complications of type-2 diabetes: UKPDS 39. BMJ 317:713–720

    Article  PubMed Central  Google Scholar 

  • Veterans Administration Cooperative Study Group on Antihypertensive Agents (1982) Comparison of propranolol and hydrochlorthiazide for the initial treatment of hypertension. Results of long-term therapy. JAMA 248:2004–2011

    Google Scholar 

  • von Armin T, for the TIBBS Investigators (1996) Prognostic significance of transient ischemic episodes: response to treatment shows improve prognosis. J Am Coll Cardiol 28:20–24

    Article  Google Scholar 

  • Weddle D, Tiihoff P, Williams M, Schuller HM (2001) Beta-adrenergic growth regulation of human cancer cell lines derived from pancreatic ductal carcinomas. Carcinogenesis 22:473–479

    Article  CAS  PubMed  Google Scholar 

  • Wellstein A, Palm D, Belz GG (1986) Affinity and selectivity of beta-adrenoceptor antagonists in vitro. J Cardiovasc Pharmacol 8(Suppl):S36–S40

    CAS  PubMed  Google Scholar 

  • Wikstrand J, Warnold T, Tuomilehto J, Olsson G, Barber HJ, Eliasson K et al (1991) Metoprolol versus diuretics in hypertension. Morbidity results from MAPHY study. Hypertension 17:579–588

    Article  CAS  PubMed  Google Scholar 

  • Wilhelmsen L, Bergland G, Elmfeldt D, Fitzsimons T, Holzgreve H, Hosie J et al (1987) Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. J Hypertens 5:561–572

    Article  CAS  PubMed  Google Scholar 

  • Williams B (2007) The obese hypertensive. The weight of evidence against beta-blockers. Circulation 115:1973–1974

    Article  PubMed  Google Scholar 

  • Wiysonge CS, Opie LH (2013) Beta-blockers as initial therapy for hypertension. JAMA 310:1851–1852

    Article  CAS  PubMed  Google Scholar 

  • Wright JT, Bakris GL, Green T (2002) Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease. Results from the AASK trial. JAMA 288:2421–2431

    Article  CAS  PubMed  Google Scholar 

  • Wu H-Y, Huang J-W, Lin H-J, Liao WC, Peng YS, Hung KY et al (2013) Comparative effectiveness of renin-angiotensin system blockers and of other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis. BMJ 347:f6008. doi:10.1136/bmj.f6008

    Google Scholar 

  • Xue H, Lu Z, Tang, WL, Pang LW, Wang GM, Wong GW et al (2015). First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension. Cochrane Database Syst Rev 1:CD008170. doi:10.1002/14651858.CD008170.pub2

  • Yamada Y, Miyajima E, Tochicubo O, Matsukawa T, Isshi M (1989) Age related changes in muscle sympathetic nerve activity in essential hypertension. Hypertension 13:870–877

    Article  CAS  PubMed  Google Scholar 

  • Yurenev AP, Dyakonova HG, Novikov ID (1992) Management of essential hypertension in patients with different degrees of left ventricular hyperterophy. Multicentre trial. Am J Hypertens 6(S):182S–189S

    Article  Google Scholar 

  • Zacharias FJ, Cowen KJ (1977) Comparison of propranolol and atenolol in hypertension. Postgrad Med J 53:111–113

    PubMed  Google Scholar 

  • Zanchetti A, Bond MG, Henning M, Neiss A, Mancia G, Dal Palu C et al (2002) Calcium antagonist lacidipine slows down progression asymptomatic carotid atherosclerosis. Principal results of the European lacidipine study on atherosclerosis (ELSA), a randonised, double-blind, long-term trial. Circulation 106:2422–2427

    Article  CAS  PubMed  Google Scholar 

  • Zhang D, Ma QY, Hu HT, Zhang M (2010) Beta2-adrenergic antagonists suppress pancreatic cancer cell invasion by inhibiting CREB, NFkB and AP-1. Cancer Biol Ther 10:19–29

    Article  CAS  PubMed  Google Scholar 

Download references

Conflicts of Interest

The author has no conflicts of interest.

Author information

Authors and Affiliations

  1. Oxonian Cardiovascular Consultancy, 42 Harefield, Long Melford, Suffolk, CO10 9DE, UK

    John M. Cruickshank

Authors
  1. John M. Cruickshank
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John M. Cruickshank .

Editor information

Editors and Affiliations

  1. Department of Clinical Science and Education Södersjukhuset, Karolinska Institutet, Stockholm, Sweden

    Md. Shahidul Islam

  2. Department of Internal Medicine and Emergency Medicine, Uppsala University Hospital, Uppsala, Sweden

    Md. Shahidul Islam

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing AG

About this chapter

Cite this chapter

Cruickshank, J.M. (2016). The Role of Beta-Blockers in the Treatment of Hypertension. In: Islam, M.S. (eds) Hypertension: from basic research to clinical practice. Advances in Experimental Medicine and Biology(), vol 956. Springer, Cham. https://doi.org/10.1007/5584_2016_36

Download citation

  • DOI: https://doi.org/10.1007/5584_2016_36

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-44250-1

  • Online ISBN: 978-3-319-44251-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation